Goldman Sachs initiates coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Neutral. PT $23.00.

The analyst comments: "Kythera's story ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE